Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Current Value
$448.461 Year Return
Current Value
$448.461 Year Return
Market Cap
$115.38B
P/E Ratio
-224.77
1Y Stock Return
26.28%
1Y Revenue Growth
10.96%
Dividend Yield
0.00%
Price to Book
7.4
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ACAD | 50.04% | $2.70B | -27.80% | 0.00% |
STTK | 45.04% | $54.42M | -50.22% | 0.00% |
TECH | 37.89% | $10.55B | +4.49% | 0.48% |
ABM | 37.61% | $3.48B | +35.26% | 1.62% |
RVTY | 37.22% | $13.38B | +23.61% | 0.26% |
PLAB | 37.10% | $1.52B | +12.34% | 0.00% |
AMGN | 35.41% | $150.48B | +6.52% | 3.20% |
AVY | 34.50% | $15.83B | +3.97% | 1.72% |
SW | 34.39% | $13.78B | +15.02% | 1.14% |
CWK | 34.10% | $3.19B | +65.60% | 0.00% |
REGN | 33.89% | $81.82B | -6.79% | 0.00% |
GMAB | 33.87% | $13.02B | -33.87% | 0.00% |
JBGS | 33.75% | $1.27B | +13.72% | 4.68% |
AKR | 33.49% | $2.99B | +69.24% | 2.92% |
ALEX | 33.41% | $1.41B | +18.14% | 4.59% |
BN | 33.15% | $85.61B | +67.30% | 0.55% |
NLY | 33.03% | $11.07B | +11.39% | 13.23% |
SITC | 32.59% | $847.27M | +59.73% | 2.42% |
INGR | 32.45% | $9.25B | +37.70% | 2.22% |
AVB | 32.42% | $32.63B | +34.34% | 2.94% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
EG | 0.08% | $15.92B | -8.98% | 2.02% |
VFC | -0.10% | $7.51B | +16.70% | 1.89% |
ACIC | -0.14% | $631.49M | +58.21% | 0.00% |
BDTX | 0.18% | $144.29M | +14.35% | 0.00% |
GHG | -0.18% | $180.98M | -36.68% | 0.00% |
VNOM | -0.18% | $5.48B | +79.62% | 3.35% |
KGS | 0.21% | $3.37B | +110.22% | 4.11% |
CRVO | 0.27% | $83.20M | +2.86% | 0.00% |
IMAX | 0.28% | $1.31B | +51.92% | 0.00% |
HRL | -0.29% | $16.30B | -8.38% | 3.81% |
VSAT | -0.31% | $876.93M | -65.78% | 0.00% |
ZCMD | 0.37% | $2.80M | -88.67% | 0.00% |
LFVN | -0.40% | $169.84M | +130.61% | 1.10% |
PGR | 0.47% | $149.10B | +57.29% | 0.45% |
NEUE | -0.49% | $40.93M | -34.13% | 0.00% |
HRTG | -0.51% | $371.89M | +58.22% | 0.00% |
ARQ | 0.54% | $332.89M | +216.80% | 0.00% |
QTTB | 0.65% | $354.34M | +188.64% | 0.00% |
IMRN | 0.65% | $10.31M | -5.04% | 0.00% |
NLOP | -0.65% | $458.04M | +94.60% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HUSA | -16.81% | $16.69M | -11.56% | 0.00% |
MNOV | -14.97% | $93.19M | +2.15% | 0.00% |
BTCT | -11.01% | $42.61M | +353.33% | 0.00% |
ZTO | -10.76% | $12.58B | -4.71% | 4.73% |
MAX | -10.14% | $681.47M | +32.02% | 0.00% |
TCTM | -9.96% | $8.10M | -42.99% | 0.00% |
AIFU | -9.90% | $67.49M | -83.02% | 0.00% |
TH | -9.59% | $839.02M | -24.49% | 0.00% |
PRPO | -9.57% | $9.10M | -13.65% | 0.00% |
CORZ | -9.49% | $4.60B | +3,201.26% | 0.00% |
OCFT | -9.30% | $80.95M | -30.38% | 0.00% |
SE | -8.96% | $60.12B | +197.12% | 0.00% |
STG | -8.83% | $35.67M | +7.92% | 0.00% |
MQ | -8.69% | $1.96B | -36.48% | 0.00% |
BEKE | -8.58% | $23.84B | +33.10% | 0.00% |
SPR | -8.08% | $3.72B | +23.27% | 0.00% |
MODV | -7.56% | $222.68M | -59.06% | 0.00% |
XGN | -7.50% | $62.26M | +127.74% | 0.00% |
IBKR | -7.16% | $20.20B | +131.83% | 0.37% |
DAVE | -6.92% | $1.04B | +1,258.83% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 55.44% | $397.87M | 0.35% |
IBB | 53.90% | $6.66B | 0.45% |
FBT | 49.94% | $1.11B | 0.56% |
FHLC | 48.56% | $2.73B | 0.084% |
VHT | 48.53% | $17.06B | 0.1% |
XLV | 48.46% | $38.41B | 0.09% |
IYH | 48.34% | $3.19B | 0.39% |
PBE | 47.78% | $258.53M | 0.58% |
IXJ | 47.77% | $3.89B | 0.41% |
RSPH | 44.75% | $885.96M | 0.4% |
FXH | 43.75% | $1.15B | 0.62% |
USMV | 42.72% | $23.89B | 0.15% |
IHE | 41.84% | $596.23M | 0.39% |
PPH | 41.39% | $592.06M | 0.36% |
FTCS | 41.12% | $8.97B | 0.54% |
HNDL | 40.74% | $780.63M | 0.97% |
XBI | 40.60% | $6.58B | 0.35% |
FDLO | 40.35% | $1.27B | 0.15% |
CGBL | 39.50% | $1.17B | 0.33% |
DLN | 39.41% | $4.41B | 0.28% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
JUCY | 0.03% | $324.29M | 0.6% |
BILZ | -0.19% | $563.02M | 0.14% |
KLIP | -0.48% | $125.85M | 0.93% |
GBIL | 0.64% | $5.60B | 0.12% |
IBTE | -1.08% | $1.70B | 0.07% |
CHIQ | 1.10% | $229.05M | 0.65% |
SOYB | -1.14% | $27.32M | 0.22% |
DBA | -1.22% | $755.88M | 0.93% |
UNG | 1.93% | $908.80M | 1.06% |
JBBB | 1.93% | $1.26B | 0.49% |
SHYD | -2.16% | $311.50M | 0.35% |
MCHI | 2.19% | $5.57B | 0.59% |
KWEB | 2.36% | $5.94B | 0.7% |
CXSE | 2.38% | $406.30M | 0.32% |
CANE | -2.71% | $17.72M | 0.29% |
FLRN | 2.91% | $2.33B | 0.15% |
DBB | 2.97% | $126.37M | 0.77% |
YEAR | -3.03% | $1.13B | 0.25% |
EQLS | -3.06% | $76.08M | 1% |
WEAT | -3.28% | $120.27M | 0.28% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -26.61% | $195.31M | 0.85% |
CTA | -22.16% | $350.27M | 0.78% |
BTAL | -17.98% | $388.04M | 1.43% |
UUP | -12.84% | $309.25M | 0.77% |
USDU | -12.64% | $201.97M | 0.5% |
TAIL | -10.11% | $67.98M | 0.59% |
GXC | -8.24% | $433.32M | 0.59% |
BOXX | -7.83% | $4.43B | 0.1949% |
KRBN | -7.63% | $242.47M | 0.85% |
FLCH | -7.60% | $151.04M | 0.19% |
HDRO | -5.97% | $164.26M | 0.3% |
KMLM | -5.95% | $353.87M | 0.9% |
CORN | -4.96% | $61.12M | 0.2% |
TPMN | -4.65% | $40.60M | 0.65% |
KCCA | -4.01% | $220.51M | 0.87% |
WEAT | -3.28% | $120.27M | 0.28% |
EQLS | -3.06% | $76.08M | 1% |
YEAR | -3.03% | $1.13B | 0.25% |
CANE | -2.71% | $17.72M | 0.29% |
SHYD | -2.16% | $311.50M | 0.35% |
MarketWatch
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Yahoo
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vertex Pharmaceuticals fair value estimate is US$859 Current...
MarketWatch
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
SeekingAlpha
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stifel 2024 Healthcare Conference November 19, 2024 8:00 AM ETCompany ParticipantsStuart Arbuckle - EVP,...
SeekingAlpha
Tweedy Browne's 13F portfolio value drops to $2.10B with reductions in top positions like Berkshire Hathaway and Alphabet. Read an update on the portfolio here.
MarketWatch
Vertex Pharmaceuticals Inc. stock rises Monday, still underperforms market
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.